Original article link AIDOT, an AI-based medical solutions company, is achieving remarkable results in global commercialization with its cervical cancer screening AI solution, ‘Cerviray AI.’ Cerviray is the world’s only AI screening solution that can both classify cervical cancer lesions into four stages and detect their locations. The solution is being rapidly adopted, especially in countries with low medical accessibility. AIDOT is driving its entry into the Central and South American markets, with regulatory processes underway in Bolivia, Honduras, and now Mexico. In Mongolia, notably, as of May 2025, Cerviray AI has reached over 15,000 cumulative screening cases and is establishing itself within the local healthcare system. Of particular note is that Cerviray AI is being used in regions with extremely limited medical infrastructure—such as Mongolia’s Gobi Desert and Bolivia’s high-altitude areas—offering accurate and rapid cervical cancer screenings even for women with poor hospital access. Its combination of mobile equipment, ease of use, and fast AI-based readings is making a tangible difference in resolving healthcare blind spots. AIDOT has surpassed its only former competitor, an Israeli company (M), in both technology and scalability, securing a practical lead in the global cervical cancer AI screening market. AIDOT’s technology enables highly precise analysis of even subtle mosaic and punctation lesions that are difficult for experts to identify. Its image-processing algorithms and massive training data support quantitative diagnoses, underpinning international competitiveness. AIDOT CEO Jaehoon Jung stated, “Cerviray AI enables fast and accurate cervical cancer screening in countries lacking medical infrastructure, already benefiting countless women. Going forward, we aim to collaborate with more nations to further improve global women's health.” 

Korea Economic TV / 2025.05.12 / Deputy Director Yang Jae-jun